Psychiatry and Neurology, Neurology · Las Vegas, NV
NPI
1477558674
Since 2005
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2440 Professional Ct, Suite 150
Las Vegas, NV, 89128
Phone (702) 405-3015
Groups this clinician bills Medicare through
Medicare paid, 2024
$264K
3,020 services
Medicare patients, 2024
672
Average age 72
Drug cost, 2024
$4.1M
2,338 prescriptions
Company payments, 2025
$10K
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shanker N Dixit was code 99439 (chronic, principal, and transitional care management), 637 times for 186 patients. In total Shanker N Dixit billed 3,020 services in 25 codes, and Medicare paid $264K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99439 Chronic, Principal, and Transitional Care Management | Office | 637 | 186 | $37.23 | $24K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 559 | 206 | $48.51 | $27K |
| 95886 Electrical Nerve Conductivity | Office | 518 | 209 | $74.82 | $39K |
| 99213 Office E&M - Established | Office | 323 | 207 | $54.79 | $18K |
| 99204 Office E&M - New | Office | 272 | 272 | $114.63 | $31K |
| 95912 Electrical Nerve Conductivity | Office | 263 | 213 | $180.29 | $47K |
| 95813 Neurologic | Office | 88 | 88 | $332.46 | $29K |
| 99203 Office E&M - New | Office | 61 | 61 | $71.76 | $4,377 |
| 95816 Neurologic | Office | 46 | 46 | $305.91 | $14K |
| 95708 Neurologic | Office | 45 | 15 | $225.27 | $10K |
| 95874 Musculoskeletal | Office | 39 | 11 | $50.37 | $1,964 |
| 64615 Musculoskeletal | Office | 21 | 15 | $85.16 | $1,788 |
| 95700 Neurologic | Office | 15 | 15 | $205.36 | $3,080 |
| 95723 Neurologic | Office | 15 | 15 | $194.46 | $2,917 |
By year: 2022 $181K for 2,334 services; 2023 $219K for 1,834 services; 2024 $264K for 3,020 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shanker N Dixit prescribed most often to Medicare patients was Botox (Onabotulinumtoxina), with 282 prescriptions and refills. In total Shanker N Dixit wrote 2,338 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Botox Onabotulinumtoxina | 282 | 794 | 108 | $372K |
| Donepezil Hcl Generic | 234 | 367 | 115 | $1,554 |
| Gabapentin Generic | 213 | 247 | 101 | $1,436 |
| Memantine Hcl Generic | 106 | 136 | 40 | $1,945 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 105 | 105 | Under 11 | $362K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 99 | 99 | Under 11 | $1.2M |
| Sumatriptan Succinate Generic | 97 | 99 | 37 | $812 |
| Duloxetine Hcl Generic | 92 | 126 | 39 | $992 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 67 | 107 | 31 | $844 |
| Propranolol Hcl Generic | 67 | 96 | 28 | $621 |
| Tizanidine Hcl Generic | 60 | 72 | 31 | $235 |
| Zonisamide Generic | 60 | 92 | 32 | $491 |
| Topiramate Generic | 58 | 78 | 22 | $458 |
| Ubrelvy Ubrogepant | 54 | 54 | 19 | $56K |
| Levetiracetam Generic | 52 | 99 | 24 | $881 |
Brand drugs: - claims; generic drugs: 1,544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shanker N Dixit $10K ($10K in general payments such as food, travel and fees) from 40 companies. The largest payer was Abbvie Inc. with $4,498.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 45 | $4,498 |
| Lundbeck LLC | 15 | $1,851 |
| Argenx US, Inc. ARGX | 13 | $444 |
| Biogen, Inc. BIIB | 15 | $439 |
| UCB, Inc. UCB.BR | 9 | $263 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $203 |
| Lilly USA, LLC LLY | 7 | $202 |
| Eisai Inc. 4523.T | 16 | $178 |
| Teva Pharmaceuticals USA, Inc. TEVA | 5 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 7 | $156 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.